Who Paid My Doc
Pluvicto
Drug Oncology
NDC 69488-010-61
General payments
$130,118,222
Research payments
$122,477,718
Through program year 2025, $130,118,222 in general payments and $122,477,718 in research payments were reported against Pluvicto (Oncology).
No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.
By program year
7 rows| Year | Kind | Amount | Payments |
|---|---|---|---|
| 2025 | General | $65,308,299 | 17,080 |
| 2025 | Research | $38,485,300 | 532 |
| 2024 | General | $64,389,523 | 12,263 |
| 2024 | Research | $19,735,422 | 315 |
| 2023 | General | $388,901 | 8,230 |
| 2023 | Research | $64,256,997 | 221 |
| 2022 | General | $31,500 | 9 |
Breakdown
The top 5 of the 100 largest recipients; each share is of general payments naming this product in 2025.
The top 5 of 82 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.
The top 5 of 52 states; each share is of general payments naming this product in 2025 where a state was reported.
Records
37,582 general · 1,068 researchEvery payment, record by record
Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.
What you are looking at
Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.